USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
Synergen Inc
Address:
1885 33rd St
Boulder, CO 80301
Phone:
N/A
URL:
N/A
EIN:
N/A
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $349,092.00 7
SBIR Phase II $440,212.00 1

Award List:

ANTIPLAQUE PROTEINS VIA GENETIC ENGINEERING

Award Year / Program / Phase:
1987 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
David I Hirsh Phd
Abstract:
N/a

DEVELOPMENT OF AMIDASES FOR USE IN BETA-LACTAM MODIFICATION

Award Year / Program / Phase:
1988 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Abstract:
Several clinically important beta-lactam antibiotics are produced through condensation of d-(-)-alpha-aminophenylacetic acid with penam and cephem nuclei in multi-step chemical processes. an efficient enzymatic process for the synthesis of these antibiotics would lead to increased product yields and… More

THERAPEUTIC CLEARANCE OF COMPLEMENT FRAGMENT C5A

Award Year / Program / Phase:
1988 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Abstract:
The overall goal of the proposed research is to provide a specific, practical means for inactivating c5a in patients at risk of adult respiratory distress syndrome (ards). c5a is a key contributory, possibly necessary factor in the pathological course of ards. the proteins capable of inactivating… More

A HUMAN IL-1 INHIBITOR FOR THE TREATMENT OF SEPTIC SHOCK

Award Year / Program / Phase:
1988 / SBIR / Phase I
Award Amount:
$49,326.00
Agency / Branch:
DOD / NAVY
Principal Investigator:
Dr charles h hannum
Abstract:
We propose to purify an il-1 inhibitor from the supernatant of monocytes cultured on plates coated with igg. this inhibitory activity has been shown to be about 22 kilodaltons in molecular weight and to inhibit il-1 in several assays, namely il-1 mediated thymocyte proliferation, collagenase release… More

ANTIPLAQUE PROTEINS VIA GENETIC ENGINEERING

Award Year / Program / Phase:
1989 / SBIR / Phase II
Award Amount:
$440,212.00
Agency:
HHS
Principal Investigator:
David I Hirsh Phd
Abstract:
Synergen, inc.'s proposed research will develop, through recombinant dna methods, new agents to control dental plaquethese will consist of an enzymatic moiety of therapeutic value fused wih an adhesive peptide that binds specifically and strongly to dental surfaces. the latter are termed adheson… More

KALLIKREIN INHIBITORS BY GENETIC ENGINEERING

Award Year / Program / Phase:
1989 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Abstract:
The aim of this research is to produce inhibitors of human kallikreins that block kallikrein-mediated conversion of kininogens into kinins. kinins are implicated in the symptoms of allergic rhinitis, asthma, and rhinovirus infection, and kallikrein inhibitors should be effective in ameliorating… More

NEW DRUG FOR PREVENTING POST-ISCHEMIC TISSUE INJURY

Award Year / Program / Phase:
1989 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Abstract:
Neutrophils are a major contributor to the cellular damage that accompanies reperfusion of ischemic tissues. it is planned to clone and produce through recombinant dna methods a human protein that blocks attachment of neutrophils to endothelial cells in vivo and thereby prevents the entry of… More

VACCINE AGAINST HAEMOPHILUS INFLUENZAE TYPE B

Award Year / Program / Phase:
1989 / SBIR / Phase I
Award Amount:
$49,766.00
Agency:
HHS
Principal Investigator:
Abstract:
This research will lead to the development of a vaccine that can be used to protect young children against infections caused by haemophilus influenzae type b (hib). the vaccine will be based on the pili that facilitate the organism's adherence to the nasopharyngeal epithelium. antibodies produced in… More